Cargando…

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience

Background: Programmed death 1 (PD-1) inhibitors—tislelizumab, toripalimab, camrelizumab, and sintilimab—are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for advanced UC. Methods: We reviewed 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Fengze, Wang, Dawei, Liu, Aina, Wang, Tianqi, Zhang, Dongxu, Yao, Huibao, Sun, Kai, Zhou, Zhongbao, Lu, Guoliang, Wu, Jitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971813/ https://www.ncbi.nlm.nih.gov/pubmed/35370654 http://dx.doi.org/10.3389/fphar.2022.837499

Ejemplares similares

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis
por: Zhang, Dongxu, et al.
Publicado: (2021)

Generation of Urothelial Cells from Mouse-Induced Pluripotent Stem Cells
por: Zhang, Dongxu, et al.
Publicado: (2022)

Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
por: Sun, Kai, et al.
Publicado: (2020)

The Efficacy and Safety of HoLEP for Benign Prostatic Hyperplasia With Large Volume: A Systematic Review and Meta-Analysis
por: Sun, Fengze, et al.
Publicado: (2022)

Meta-Analysis of the Safety and Efficacy of α-Adrenergic Blockers for Pediatric Urolithiasis in the Distal Ureter
por: Sun, Fengze, et al.
Publicado: (2022)

The efficacy of intravaginal electrical stimulation (IVES) in treating female with urinary incontinence symptom from meta-analysis of nine randomized controlled trials
por: Yao, Huibao, et al.
Publicado: (2022)

PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study
por: Huang, Guili, et al.
Publicado: (2022)

PIMREG is a prognostic biomarker involved in immune microenvironment of clear cell renal cell carcinoma and associated with the transition from G1 phase to S phase
por: Yao, Huibao, et al.
Publicado: (2023)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Systematic Review and Meta-Analysis of 16 Randomized Controlled Trials of Clinical Outcomes of Low-Intensity Extracorporeal Shock Wave Therapy in Treating Erectile Dysfunction
por: Yao, Huibao, et al.
Publicado: (2022)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

The role of three-dimensional model in preoperative communication before partial nephrectomy and postoperative management
por: Tang, Gonglin, et al.
Publicado: (2023)

Distal end of Double-J ureteral stent position on ureteral stent-related symptoms: A systematic review and meta-analysis
por: Bao, Xingjun, et al.
Publicado: (2022)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
por: Wang, Wei, et al.
Publicado: (2023)

Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
por: Umetsu, Ryogo, et al.
Publicado: (2021)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
por: Fang, Zhihong, et al.
Publicado: (2023)

Meta-Analysis of the Efficacy and Safety of Ketamine on Postoperative Catheter-Related Bladder Discomfort
por: Lu, Youyi, et al.
Publicado: (2022)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System
por: Yang, Renjun, et al.
Publicado: (2022)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bian, Sainan, et al.
Publicado: (2021)

Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database
por: Peng, Jing, et al.
Publicado: (2022)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study
por: Zheng, Xiaowei, et al.
Publicado: (2022)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
por: Zhou, Zhi-Xuan, et al.
Publicado: (2022)

GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS
por: Yang, Zheng, et al.
Publicado: (2022)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

Current landscape and tailored management of immune-related adverse events
por: Liu, Wenhui, et al.
Publicado: (2023)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence
por: Bérard, Anick, et al.
Publicado: (2021)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8r2bvs1uok4qj8vufu13ja5uh6